SEFA 1024
Alternative Names: 1024; NST-1024; SEFA-1024Latest Information Update: 28 Mar 2026
At a glance
- Originator Pronova BioPharma
- Developer NorthSea Therapeutics
- Class Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypertriglyceridaemia
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for phase-I development in Hypertriglyceridaemia(In volunteers) in United Kingdom (PO, Capsule)
- 11 Apr 2025 NorthSea Therapeutics completes a phase II trial in Hypertriglyceridaemia in the US (PO) (NCT05889156)
- 18 Mar 2024 SEFA 1024 is still in phase I trial for Hypertriglyceridemia in United Kingdom (NorthSea Therapeutics pipeline, March 2024)